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Purpose: In this systematic review, the existing evidence of available hypoxia-associated molecular
response biomarkers in esophageal cancer (EC) patients is summarized and set into the context of the role
of hypoxia in the prediction of esophageal cancer, treatment response and treatment outcome.
Methods: A systematic literature search was performed in Web of Science, MEDLINE, and PubMed data-
bases using the keywords: hypoxia, esophagus, cancer, treatment outcome and treatment response.
Eligible publications were independently evaluated by two reviewers. In total, 22 out of 419 records were
included for systematic review. The described search strategy was applied weekly, with the last update
being performed on April 3rd, 2017.
Results: In esophageal cancer, several (non-)invasive biomarkers for hypoxia could be identified.
Independent prognostic factors for treatment response include HIF-1a, CA IX, GLUT-1 overexpression
and elevated uptake of the PET-tracer 18F-fluoroerythronitroimidazole (18F-FETNIM). Hypoxia-associated
molecular responses represents a clinically relevant phenomenon in esophageal cancer and detection of
elevated levels of hypoxia-associated biomarkers and tends to be associated with poor treatment outcome
(i.e., overall survival, disease-free survival, complete response and local control).
Conclusion: Evaluation of tumor micro-environmental conditions, such as intratumoral hypoxia, is impor-
tant to predict treatment outcome and efficacy. Promising non-invasive imaging-techniques have been
suggested to assess tumor hypoxia and hypoxia-associated molecular responses. However, extensive val-
idation in EC is lacking. Hypoxia-associated markers that are independent prognostic factors could poten-
tially provide targets for novel treatment strategies to improve treatment outcome. For personalized
hypoxia-guided treatment, safe and reliable makers for tumor hypoxia are needed to select suitable
patients.
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Hypoxia is one of the hallmarks of cancer and has been associ-
ated with a more aggressive tumor phenotype, a higher likelihood
of metastatic progression and resistance to (chemo)radiotherapy
[1]. Hypoxia occurs when tissue oxygen demand (e.g., increased
metabolism) exceeds oxygen supply (e.g., acute and/or chronic
vascular changes, anemia, malfunctioning hemoglobin). In normal
tissue, acute hypoxia (i.e., perfusion-limited) is resolved by physi-
ological homeostasis while in cancerous tissue, additional chronic
hypoxia (i.e., diffusion-limited) is more likely to manifest. The
rapid and uncontrollable tumor growth requires large amounts of
nutrients and therefore triggers neo-angiogenesis. However, the
resulting tumor neo-vasculature is highly chaotic and inefficient.
Oxygenation of tumor regions surrounding perfused blood vessels
therefore depends on a diffusion-gradient, relative to the intravas-
cular oxygen partial pressure (pO2). Generally, the diffusion-
gradient is limited to 100–180 mm, thus inducing chronic hypoxia
in remote regions [1].
Clinically, hypoxia is thought to be a key factor contributing to
treatment resistance and poor patient prognosis [2]. Although
neoadjuvant therapy (i.e., CROSS regimen with weekly carboplatin
(2 mg/ml/min AUC) and paclitaxel (50 mg/m2) for 5 weeks, concur-
rent radiotherapy (41.4 Gy in 23 fractions, 5 days per week), fol-
lowed by surgery) has been proven to be valuable in esophageal
cancer (EC), prognosis remains dismal with approximately 20%
complete responders (5 yr overall survival = 20–30% [3,4]), making
EC the sixth most lethal cancer type in 2012, worldwide [5]. In
2016, over 15.000 patients died from EC in the USA alone [5]. Most
EC contain hypoxic areas with a higher percentage in the adenocar-
cinomas, potentially explaining the poor treatment outcome for
these patients [6]. About half of the patients treated with definitive
chemoradiation will suffer from a locoregional recurrence. For
effective radiation treatment, the presence of molecular oxygen
is essential. Under normoxic conditions, ionizing radiation leads
to the formation of free radicals and reactive oxygen species
(ROS), which can damage DNA. Free radicals produced in the crit-
ical target can be fixed in the presence of oxygen, leading to irre-
versible DNA damage. In hypoxic conditions however, free
radicals are reduced and hypoxic regions becomes 2–3 times more
radio-resistant, which may explain low rates of complete response
(CR) and local control (LC) [1,7]. Accordingly, patients with hypoxicEC might need a different, personalized treatment approach to
reach therapeutic success.
Since tumor hypoxia cannot be predicted based on clinical size,
stage, or grade, there is a need for molecular biomarkers that can
assess hypoxic status in EC. Such biomarkers could be used to
detect hypoxic tumor status at an early stage, evaluate treatment
response, predict prognosis in EC patients and select patients for
suitable, personalized treatment options.
In this systematic review, we provide an overview of hypoxia
response-associated biomarkers in EC patients and aim to evaluate
the prognostic value of elevated expression rate of hypoxia-
associated biomarkers with regard to treatment outcome and effi-
cacy [i.e., overall survival (OS), disease-free survival (DFS), CR, and
LC]. Markers that are independent prognostic factors could poten-
tially provide targets for novel treatment strategies. In addition,
several known methods to improve treatment outcome will be dis-
cussed in relationship to these hypoxia-associated biomarkers.2. Material and methods
2.1. Systematic search strategy
The research question for this systematic review was defined
as: ‘‘What are the known hypoxia-associated molecular markers
in patients with EC and how does elevated expression associate
with treatment outcome and response?”.
To consider the research question, a comprehensive PRISMA-
based literature search was performed to identify relevant studies
published in PubMed (National Center for Biotechnology Informa-
tion, NCBI), MEDLINE (U.S. National Library of Medicine, using
NCBI), or Web of Science (Thomson Reuters). The electronic data-
bases were explored using a PICOS-based search string containing
a free-text or Medical Subject Headings (MeSH) construction of 5
key search terms: ‘hypoxia’ AND ‘esophagus’ AND ‘cancer’ AND
(‘treatment outcome’ OR ‘treatment efficacy’). For each search
term, all known synonyms and associated keywords were included
in the search string using Boolean OR-operators. A detailed
description of the entire search strings can be found in Appendix
A1 [8]. The complete search strategy was applied weekly, with
the last update being performed on April 3rd, 2017.
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Fig. 1. Flowchart of information through different phases of systematic review. *Reasons for exclusion on full-text level were: not fitting PICOS-based research question
(n = 6), use of preclinical tumor models (n = 4), or unsuitable to extract survival data (n = 1).
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Articles were eligible for inclusion when corresponding to the
predetermined eligibility criteria: (1) the patient population con-
sisted of human adults diagnosed with esophageal cancer or clini-
cally acquired EC tissue samples; (2) the index tests were all tests
able to assess tumor hypoxia; (3) treatment outcome had to be
evaluated and correlated with hypoxia. Only full-text articles writ-
ten in English were retrieved from the electronic databases. If full-
text content was not available to us, the corresponding author was
contacted to retrieve the printed publication. Next, duplicate find-
ings were manually discarded to ensure that no data overlap
occurred. Further selection was performed by applying several
exclusion criteria: (1) reviews, letters, abstracts, case studies,
etc.; (2) studies using only esophageal cell lines or animal-based
tumor models; (3) studies aiming to investigate the molecular
mechanisms of hypoxia; (4) studies that did not correlate expres-
sion rate of hypoxia-associated markers with treatment outcome
or efficacy (i.e., CR, LC, OS, or DFS). Additional eligible articles were
retrieved by manually cross checking reference lists of relevant
articles and reviews (citation tracking). Furthermore, databases
were searched to retrieve studies exploring additional methods
for non-invasive hypoxia-assessment in cancer patients by per-
forming a secondary search including the MeSH-terms ‘Hypoxia’
AND (‘MRI’ OR ‘SPECT’ OR ‘PET’ OR ‘CT’). This search was notspecific for esophageal cancer and will be reviewed in the second
part of this manuscript.
2.3. Data extraction
Two investigators (J.P. and L.VDV.) performed each step of this
protocol independently (i.e., systematic search, defining eligibility,
and data extraction). In cases of disagreement and consensus could
not be reached, a third party (L.D.) was consulted to adjudicate.
From the included articles, data was extracted concerning study
characteristics (i.e., author, publication year), patient characteris-
tics (i.e., number of subjects, country of origin, specimen type,
tumor cell type), measurement characteristics (i.e., method of
quantifying hypoxia, marker type, definition of hypoxia, percent-
age of hypoxic elements), and treatment strategy and response
outcome characteristics (i.e., OS, DFS, CR, and LC). CR is defined
as the total disappearance of a tumor, and LC as the arrest of cancer
growth at the site of origin (i.e., stable tumor volume). Survival is
assessed by OS, defined as the time interval from end of primary
therapy until last known survival data or death, and DSF that is
defined as the time interval after primary treatment and the first
signs of recurrence, metastasis, or cancer-related disease. Further-
more, statistical outcome was extracted with p-values defining the
prognostic/predictive power. P-values <0.05 indicated statistically
significant differences in treatment outcome between high and
Table 1
Extracted data concerning Overall survival (OS) and Disease-free survival (DFS) in esophageal squamous cell carcinoma (SCC) and adenocarcinoma (AC). IHC = immunohistochemistry. (*) P-values <0.05 indicate significant differences.
Ref Author publication
year
Country Specimen Index test Marker hypoxia criteria (threshold
expression rate/definition of hypoxia
Tumor type #
samples
Hypoxic
sample
(%)
OS DFS Independent
Prognostic
factorhypoxic
vs. non-
hypoxic
sample
P-value*
Kaplan-
Meier
model
Cox proportional hazard
model
hypoxic
vs. non-
hypoxic
sample
P value*
Kaplan-
Meier
model
Cox proportional hazard
model
Univariate
P-value*
Multivariate
P-value*
Univariate
P-value*
Multivariate
P-value*
[9] Birner et al. 2011 Austria Surgical IHC CAIX >median staining intensity* staining
rate
All 330 44.5% 30% vs.
54%
0.001 <0.001 0.009 24%
vs.52%
0.001 <0.001 0.001 Yes
AC 182 46.7% 37%
vs.59%
0.001 0.007 0.027 33% vs.
55%
0.001 0.007 0.019 Yes
SCC 148 41.9% 19%
vs.48%
0.001 0.001 0.043 12% vs.
45%
0.001 <0.001 0.01 Yes
[10] Chen et al. 2009 China Surgical IHC Beclin-2 <10% cytoplasm/cytomembrane
staining
SCC 54 33.3% – 0.004 – – – – – – –
HIF-1 a >mean cytotoplasmic expression SCC 54 46.3% – 0.052 – – – – – – –
Beclin-2
and HIF-
1a
Low Beclin-2 and High HIF-1a SCC 54 24.1% – 0.001 – – – – – – –
[11] Chiba et al. 2010 Japan Biopsy IHC GLUT-1 >30% membrane expression SCC 25 28.1% – – – – 28.5% vs.
30.1%
0.0405 0.0405 0.016 yes
[12] Driessen
et al.
2006 The
Netherlands/
Belgium
Surgical IHC CAIX >median membranous staining
intensity
AC 39 49.0% 27% vs.
47%
0.008 – 0.017 – – – 0.041 yes
VEGF >median cytoplasmic staining
intensity
AC 39 69.2% – – >0.05 >0.05 – – >0.05 >0.06 no
[13] Jomrich et al. 2014 Austria Surgical IHC CAIX 10% stromal staining Total 361 11.6% 28% vs.
44%
0.013 – 0.196 25% vs.
37%
0.007 – 0.081 no
AC 206 11.2% 42% vs.
47%
0.142 – 0.256 40% vs.
41%
0.121 – 0.055 no
SCC 155 12.3% 10% vs.
39%
0.045 – 0.933 8% vs.
33%
0.029 – 0.807 no
[14] Katsuta et al. 2005 Japan Surgical IHC HIF-1 a >10% nuclear or distinct cytoplasmic
staining
SCC 48 70.8% 70.6% vs.
92.9%
0.3408 – – 20.6% vs.
0%
0.09 – – –
VEGF >30% cytoplasmic staining SCC 48 60.4% 65.5% vs.
89.5%
0.4659 – – 26.1% vs.
5.6%
0.22 – – –
[15] Kimura et al. 2004 Japan Surgical IHC HIF-1 a >mean nuclear/cytoplasmic
expression
SCC 47 36.1% – 0.044 – – – – – – –
VEGF >10% cytoplasmic staining SCC 47 53.2% – 0.0012 – – – – – – –
[16] Koukourakis
et al.
2001 Greece Biopsy IHC HIF-1 a nuclear staining SCC 37 51.0% – 0.08 – – – 0.14 – – –
HIF-2 a nuclear staining SCC 37 13.5% – 0.03 – – – 0.1 – – –
[17] Kurokawa
et al.
2003 Japan Surgical IHC HIF-1 a >10% nuclear or distinct cytoplasmic
staining
SCC 130 30.8% 40% vs.
58%
0.0007 0.0011 0.1669 – – – – no
[18] Ling et al. 2006 Germany Biopsy
+ Surgical
IHC HIF-1 a
protein
nuclear staining Total 53 33.3% – – 0.53 – – – – – no
RNA
assay
HIF-1 a
mRNA
Ratio tumor-to-normal epithelium
>1
Total 53 53.8% – – 0.78 – – – – – no
AC 22 15.4% – – 0.59 – – – – – no
SCC 31 38.5% – – 0.23 – – – – – no
[19] Matsuyama
et al.
2004 Japan Surgical IHC HIF-1 a >mean nuclear/cytoplasmic
expression
SCC 215 95.0% 43% vs.
52%
0.109 0.112 – 47% vs.
55%
0.024 0.027 0.142 no
[20] Munipalle
et al.
2011 United
Kingdom
Biopsy IHC HIF-1 a 10% nuclear staining SCC 36 52.8% 26% vs.
18%
0.908 – <0.001 – – – – yes
[21] Ogane et al. 2010 Japan Surgical IHC HIF-1 a nuclear staining SCC 96 67.7% – 0.034 0.0322 0.227 – 0.019 – – yes
[22] Ogawa et al. 2011 Japan Biopsy IHC HIF-1 a >10% staining SCC 25 18.2% – >0.05 – – 18.2% vs.
39.8%
0.0009 0.0009 0.001 yes
[23] Schreurs
et al.
2014 The
Netherlands
Patient PET scan 18F-FDG SUVmax (FDG) > 3.67 Mix 47 – 23.3%
vs.56.6%
0.301 – – 17% vs.
62%
0.022 – – –
[24] Sohda et al. 2004 Japan Biopsy IHC HIF-1 a >10% cell staining Mix 65 58.5% – 0.472 – – – – – – –
[25] Takala et al. 2011 Finland Surgical IHC HIF-1 a >5% nuclear staining Mix 80 71.3% – 0.223 – – – – – – –
VEGF >25% cytoplasmatic staining Mix 84 71.4% – 0.84 – – – – – – –
[26] Tanaka et al. 2008 Japan Surgical IHC CAIX >median staining rate and intensity SCC 127 59.8% 33.3% vs.
66.5%
0.0003 0.0006 0.7859 – – – – no
[27] Tzao et al. 2008 Taiwan Surgical IHC HIF-1 a >10% positive staining SCC 85 61.2% – 0.002 – 0.044 – – – – yes
VEGF >10% positive staining SCC 85 65.9% – 0.001 – 0.035 – – – – yes
[28] Winther
et al.
2013 Denmark Biopsy Gene
Clustering
15
hypoxia-
assoc.
genes
weighted hypoxia gene expression
signature
Mix 56 31.0% 12.5% vs.
48.6%
0.07 >0.05 0.11 12.5% vs.
48.6%
0.13 0.02 0.22 no
[30] Zhang et al. 2014 China Surgical IHC HIF-1 a >median staining intensity * staining
rate
SCC 136 52.2% 25.3% vs.
36.9%
0.031 – 0.22 22.5% vs.
35.4%
0.042 – 0.35 no
Locoregional
SCC
67 41.8% 32.1% vs.
51.3%
0.044 – 0.039 32.1% vs.
51.3%
0.049 – 0.051 yes
Metastatic
ESSC
69 62.3% 11.5% vs.
16.3%
0.847 – – – 0.563 – – no
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J. Peerlings et al. /Methods 130 (2017) 51–62 55low percentages of hypoxia-associated markers based on the
reported threshold of hypoxia.3. Results
3.1. Literature search
As presented in Fig. 1, a total of 419 records were initially iden-
tified in Web of Science (n = 182), PubMed (n = 215) using free-text
search strings and in MEDLINE (n = 22) using MeSH-terms. After
imposing language-restrictions and removing duplicate findings
(n = 121), 244 full-text records remained. Further screening of
records’ title resulted in 85 potentially eligible studies by excluding
articles that clearly stated terms did not fit the inclusion criteria
(e.g., different tumor-types, reviews, meta-analyses, etc.). Next,
abstracts of the remaining 85 articles were screened and based
on the exclusion criteria, we excluded reviews (n = 4), papers that
studied the molecular pathways of hypoxia (n = 7), and papers that
did not evaluate esophageal cancer (n = 16), or treatment outcome
(n = 13), or studied the effects of hypoxia (n = 14). Finally, the full-
text content of 31 articles was assessed for eligibility and 11 stud-
ies were excluded for following reasons: studies had different
study objective than our PICOS-based research question to assess
esophageal tumor hypoxia (n = 6), the use of preclinical animal-
based tumor models or esophageal cell lines (n = 4), and studies
that did not allow the extraction of survival data or clinical effec-
tiveness data (n = 1). Through citation tracking, additional papers
(n = 2) were included that fitted the eligibility criteria. In total,
22 studies were included to be systematically reviewed [9–30].3.2. Data extraction
Several studies confirm the presence of endogenous hypoxia-
associated markers in esophageal cancer patients. The clinical
impact of hypoxia in treatment outcome (i.e., OS, DFS, CR, and
LC) is summarized in Tables 1 and 2, respectively. In both tables,
clinical impact was defined by Kaplan-Meier analyses (log-rank
test) and Cox proportional hazard model (uni- and multi-variate
analyses).
In general, we found mainly endogenous tissue markers (HIF-
1a, carbonic anhydrase IX and GLUT-1) with prognostic value
and ability to predict treatment response in EC. We found only
one study with non-invasive imaging including 18F-FETNIM PET
which correlated hypoxia to chemoradiotherapy response in EC.3.2.1. Hypoxia-inducible factor (HIF)
Hypoxia-inducible factor (HIF) is the master protein in regulat-
ing the response of cells to changing oxygen levels and recognizes
the hypoxia response element (HRE) on the untranslated region of
over 150 genes involved in cell survival, tumor metabolism, prolif-
eration, and angiogenesis [31,32]. HIF-1 exists as a heterodimer
protein composed of constitutively expressed HIF-1b complexed
with one of three subunits (HIF-1a, HIF-2a or HIF-3a). Synthesis
of HIF-1a is regulated via O2-independent mechanisms whereas
degradation is primarily 02-dependent. Thus, HIF-1a upregulation
could be a promising endogenous marker of hypoxia in EC. Inter-
estingly, strong immunoreactivity for HIF-1a was presented more
often in esophageal squamous cell carcinomas (ESCC) tumor tissue
than in adenocarcinoma (AC) (p = 0.009) [25]. HIF-1a could be dif-
ferently upregulated in ESCC than in AC. Together with molecular
mutations and epigenetic alterations, the difference in outcome
and treatment response of the two histologic subtypes could be
explained [4]. Given the scarce data of HIF-1a in AC, no clear
conclusion can be drawn regarding clinical outcome.
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of HIF-1a in ESCC has been investigated [3]. They reported that in
univariate analyses HIF-1a overexpression was significantly asso-
ciated with poor OS (p < 0.001, 10 studies), and DFS (P = 0.013, 2
studies). These findings are in accordance with most overlapping
studies included in this review. However, Munipalle et al. [20]
showed that HIF-1a overexpression was not correlated with OS
in a European population (p = 0.908), contrary to the reported
Japanese/Chinese population [20]. Presumably, this information
was overlooked in the aforementioned meta-analysis because
11/12 studies included a Japanese or Chinese population
(906/942 ESCC patients) and only 1 study was included with
36/942 ESCC patients originating from the UK. In multivariate
analyses, opposing results have been presented as some studies
indicated that HIF-1a overexpression is an independent prognos-
tic factor for survival [21,27], while some studies report the
contrary [17,18,30]. In the study by Zhang et al. [30], the prognos-
tic power of HIF-1a overexpression could be lost by including
metastatic/recurrent ESCC in the patient cohort [30]. Therefore,
further clarification is needed in a large prospective study that
includes both uni- and multivariate analyses to investigate
differences in patient cohort, histological subtype, and pathologic
origin (primary or metastatic EC).
In early stage esophageal cancer, HIF-1a expression in tumor
tissue is associated with lower CR rates to local therapies such as
photodynamic therapy (PDT) and concurrent chemoradiotherapy
(CCRT) [16,22,24,29]. This suggests that low HIF-1a levels in EC
may be a good indicator for early treatment response in otherwise
treatment-resistant hypoxic tumors. The significant correlation
between HIF-1a and CR has been confirmed by Ping et al.
(p = 0.001, 4 studies) [3].
3.2.2. Carbonic anhydrase (CA IX)
Carbonic Anhydrase IX (CA IX) belongs to the family of zinc
metalloenzymes with presence in normal stomach, intestinal
and gall bladder tissue. It is involved in maintaining the cells
pH-homeostasis by the reversible hydration of carbon dioxide
into bicarbonate and hydrogen [33]. CA IX is over-expressed in
hypoxic solid tumors through the HIF-1a activation cascade.
Compared to HIF-1 a, CA IX is a stable and sustained marker
of hypoxia with a half-life of 38 h [9,34]. In general, elevated
membraneous CA IX was mainly found at the tumor center or
at the border of tumors with expression rates being approxi-
mately 45–60% [9,12,26]. In 2008, Tanaka et al. reported that
although hypoxia-induced CA IX expression correlated with more
aggressive clinicopathological parameters and poor outcome,
tumor related CA IX expression in ESCC was not an independent
prognostic factor in multivariate survival analysis [26]. In con-
trast, Driessen et al. [12] showed that CA IX is a significant
determinant in AC, and an independent prognostic factor for
OS (p = 0.017) and DFS (p = 0.041) [12]. This was confirmed in
a more recent study by Birner et al. [9] in an evenly-
distributed patient cohort of ESCC and AC [9]. In a meta-
analysis by van Kuijk et al. [33], EC-specific subgroup-analyses
reported significant association between CA IX expression and
both OS and DFS, respectively (p < 0.001) [33]. High CA IX
expression was thus regarded as an adverse prognostic marker
in EC. Furthermore, the expression of CA IX in tumor-
surrounding stroma has also been significantly linked to shorter
OS (p = 0.013) and DFS (p = 0.007) in a large cohort-study
(n = 155 ESCC, n = 206 AC) [13]. It has been postulated that the
difference in clinical behavior between ESCC and AC, could be
related to a significant correlation between CA IX and HER-2
and/or a VEGF expression [9,12]. Nevertheless, these findings
indicate the importance of this hypoxia-associated marker in
disease progression and treatment resistance.3.2.3. Other hypoxia-associated markers
The expression of glucose-transporter-1 (GLUT-1) is upregu-
lated in hypoxic condition by HIF-1. In immunohistochemistry
(IHC) analyses, GLUT-1 expression appeared to be a surrogate mar-
ker for hypoxia but also seemed to be prognostic factor for DFS and
predictive for initial response to CCRT and LC [11].
Vascular endothelial growth factor (VEGF) is a transcriptional
target for HIF and stimulates angiogenesis in EC [25]. Contradicting
findings have been reported concerning the prognostic value of
VEGF. In AC patients or in a mixed cohort, studies reported no asso-
ciation between VEGF expression and prognosis [12,25]. In ESCC,
however, VEGF expression was regarded as an independent prog-
nostic factor of OS [15,27].
3.2.4. Non-invasive imaging techniques
Non-invasive molecular imaging using positron-emission
tomography (PET) has been shown to specifically detect hypoxic
cell clusters in individual tumors using several 2-nitroimidazole
derivatives [35–41]. Viable hypoxic cells are marked by 2-
nitroimidazole derivatives through irreversible electron-reduction
mechanisms involving nitroreductase enzymes such as cyto-
chrome P450 reductase. Four clinically used, FDA approved
hypoxia PET-tracers are presented in Table 3 [6,29,35,36,42–46].
It has been shown that 18F-fluoromisonidazole (18F-FMISO)
allows visualization of hypoxic areas in a variety of tumors
although data on EC remain scarce. In a study by Brink et al. [6],
33/38 patients with EC presented noticeable hypoxic volumes
[6]. Standard uptake values (SUV) of 18F-FMISO were shown to
be significantly higher in AC (n = 20, SUVmean = 1.93 ± 0.43) than
in ESCC (n = 18, SUVmean = 1.56 ± 0.25) (P < 0.01) [6]. However,
the ability to visualize hypoxia differs in various cancer-types.
For example, a significant correlation between 18F-FMISO uptake
and tumor markers from IHC (e.g., microvessel density, HIF-1alfa,
VEGF, and GLUT-1) have been reported in head-and-neck cancer,
whereas no correlation has been published in non-small-cell-
lung cancer (NSCLC) [35,37].
In untreated ESCC, Yue et al. evaluated the spatiotemporal
variability of hypoxia and assessed the ability to predict
clinical response after CCRT using the PET-marker
18F-fluoroerythronitroimidazole (18F-FETNIM) [29]. In this
study, 18F-FETNIM presented pharmacokinetic advantages over
18F-FMISO and SUVmax (18F-FETNIM) was found to be predictive
for clinical response to CCRT (P = 0.041). A higher baseline SUVmax
(18F-FETNIM) of 5.9 was found in non-responders, while complete
or partial responders showed SUVmax (18F-FETNIM) of 3.2 and 4.5,
respectively.
Another promising PET-tracer able to visualize tumor hypoxia is
18F-3-Fluoro-2-(4-((2-nitro-1H-imidazol-1-yl)methyl)-1H-1,2,3-tri
azol-1-yl)propan-1-ol (18F-HX4) [36,47,48]. Klaassen et al. [44]
first studied the feasibility and repeatability of 18F-HX4 imaging
in esophageal cancer [44]. Amount and location of elevated 18F-
HX4 uptake showed good repeatability in 19 EC patients (AD and
SCC) suggesting that 18F-HX4 PET could be a promising reliable
tool to monitor tumor hypoxia in EC patients. Overall maximal
tumor-to-background (TBRmax, mean ± SD) was found to be
1.87 ± 0.46 in EC, 4 h post-injection. 18F-HX4 has proven to be clin-
ically useful in the non-invasive detection of tumor hypoxia also in
other tumor-types (e.g., head & neck and lung cancer) (Fig. 2)
[37,38,40,49].
Although not yet assessed in EC, several other PET-tracer are
known to visualize tumor hypoxia. For example, 18F-FAZA has
shown promising results in correlating hypoxia in head-and-neck
cancer with outcome after CCRT [50]. Less popular clinical
PET-tracers include non-nitroimidazole Cu-ATSM [Cu(II)-diacetyl-
bis(N4-methylthiosemicarbazone)], 18F-FETA, and 18F-EF5. Although
several studies have presented Cu-ATSM as a hypoxia marker for
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Fig. 2. Clinical 18F-HX4 PET/CT imaging of hypoxic non-small cell lung cancer (4 h post-injection). The primary lung tumor (white triangle) is depicted in transversal (a,c) and
coronal plane (b,d), measured before (a,b) and after hypoxia-modified chemoradiotherapy (c,d). SUV(18F-HX4) ranged from 0.2 to 1.8.
Table 3
Overview of 2-nitroimidazole PET-tracers able to visualize tumor hypoxia in esophageal cancer. (*) missing data was substituted with known features in lung cancer. (**)Tumor to
background ratio was defined as the ratio of SUVmax (tumor) over SUVmax (spleen).
[18F]-FMISO [18F]-FETNIM [18F]-FAZA* [18F]-HX4
Hypoxia PET-tracers
Year of publication [44] 1987 1995 2002 2010
Stability Metabolites in blood
and urine
Fewer metabolite-formation
than FMISO
Very few metabolite-formation
(10–15%) [46]
Few metabolite-formation
(18%) [47]
Clearance Very slow Hepatobiliary Slow Renal Fast Renal Very fast Renal
Optimal scantime No plateau 2 h p.i. [29] 2 h p.i. [37] 3–4 h p.i. [45]
TBRmax (mean ± SD) Not defined 2.41 ± 0.6* [37] 0.98 ± 0.19 [46] 1.87 ± 0.46 [45]
Hypoxic threshold TBR > 1.2 [6] TBR** > 1.3 [29] TBR > 1.4 [82] TBR > 1.0–1.4 [45]
Hydrophilicity (logP) [43] 0.4 0.77 0.4 0.69
* NOT investigated in Esophageal cancer patients.
** SUVmax ratio Tumor-to-spleen.
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cancer, cellular Cu-ATSM retention is affected by multiple mecha-
nisms in addition to hypoxia [51,52]. Thus Cu-ATSM would not be
a pure marker for hypoxia. Recently, 89Zr-labeled cG250 mono-
clonal antibodies have been show to quantify and map CA IX
expression in preclinical models and head-and-neck cancer using
PET [53]. Directly labeling CA IX for hypoxia-related PET-tracers
has also been investigated [54–56].
Ideal PET-tracers for hypoxia should be able to reach hypoxic
cells in perfusion-limited microenvironments, have an oxygen-
specific retention mechanism, and have a rapid and complete
clearance of unbound radioactive tracer (i.e., hydrophilic) [42].
These properties ensure safe and optimal PET-imaging of tumor
hypoxia. Unfortunately, none of the presented PET-tracers com-
pletely meet all these requirements (Table 3).
Another non-invasive technique that can detect hypoxia is mag-
netic resonance imaging (MRI) using exo- or endogenous contrast
agents, and MR spectroscopy techniques such as electron paramag-
netic resonance and hyperpolarized metabolic MRI [57]. Although
MRI has not yet been used to investigate tumor hypoxia in EC, it
shows promising results in other tumor types. In cervical cancer,for example, several studies have shown a correlation between
tumor hypoxia and dynamic contrast enhanced (DCE-)MRI, using
gadoliniumbolus-injection, anddemonstrated the ability to identify
patients with hypoxia-related treatment resistance [58]. However,
DCE-MRI estimates tumor perfusion and could therefore not assess
the full extent of chronic tumor hypoxia. Similarly, blood-oxygen
level dependent (BOLD)-MRI has been reported to be sensitive to tis-
sue oxygenation by indirectly correlating deoxyhemoglobin-
induced changes in MR signal to pO2. In clinical trials, BOLD-MRI
has been reported tomap chronic hypoxic regions in prostate cancer
by correlation with pimonidazole staining and evaluate hypoxia in
breast cancer through correlation with CA IX expression (r = 0.616,
P < 0.001) [59,60]. Although these MRI-techniques could be used
as surrogate markers for tumor hypoxia, measurements are usually
indirect and sensitive to image-related artifacts [61].
4. Discussion
In this study, we performed a systematic literature search,
reviewed the various hypoxia-associated markers used in EC
patients, and assessed the clinical impact of hypoxia in treatment
58 J. Peerlings et al. /Methods 130 (2017) 51–62outcome (i.e., CR, LC, OS and DFS). Most included studies investi-
gated invasively acquired hypoxia-associated markers (i.e., HIF
and CA IX) in IHC analyses. Although all studies confirmed the
presence of tumor hypoxia in esophageal cancer, the prognostic
value was not consistent across all studies. Discrepancies might
arise from methodology differences for hypoxia detection and
quantification. In addition, diverging findings could arise from dif-
ferences in tumor cell type (AC vs. SCC) or from population differ-
ences (Western vs. Far Eastern) in the study cohort. Nevertheless,
HIF-1a overexpression could be regarded as a molecular biomarker
for hypoxia-response and could be associated with treatment out-
come and clinical response to CCRT and PDT in Asiatic patients
with EC. In AC, CA IX levels in both tumor stroma and cell mem-
brane are indicative for hypoxic status and prognostic for OS and
DFS. However, we found contradicting results from multivariate
survival analyses in studies with HIF-1a as well as with CA IX.
These findings support the need to further elucidate the complex
molecular mechanism of tumor hypoxia and construct more reli-
able prediction models. Because invasively acquired biomarkers
report unreliable results and are lacking the ability to capture the
full intricacies of tumor hypoxia and its heterogeneity, there is a
need for robust and quantitative biomarkers to detect hypoxia or
hypoxia-associated responses in EC and determine complete tumor
oxygenation. Furthermore, clinical assessment of hypoxic status
needs to be performed repeatedly (i.e., before and during
(chemo)radiation treatment), since hypoxia is a dynamic process
and reoxygenation could occur after irradiation [62,63]. Non-
invasive imaging using radioactive PET-tracers shows great
promise in repeatable and quantitative detection of hypoxic
sub-regions in the entire tumor, although further validation of
the clinical and prognostic value in EC is required.
Combining PET-imaging with MRI in a multimodal hybrid sys-
tem (i.e., PET/MRI) might be the solution to identify potential
new biomarkers and validate hypoxia-associated biomarkers in
EC patients. Recently, Simoncic et al. [64] demonstrated a high cor-
relation between 18F-FMISO uptake parameters and DCE-MRI
kinetic parameters in head-and-neck cancer patients (n = 6) [64].
However, the vascular data of dynamic PET and DCE-MRI was
not exactly the same and the further development of simultaneous
PET/MRI is encouraged to visualize hypoxic status. In addition to
DCE- and BOLD-MRI, new techniques to assess tissue oxygenation
are under development. Mapping oxygen by imaging lipids relax-
ation enhancement (MOBILE) detects variations in oxygenation
based on MR relaxation rates of tissue lipids, instead of blood-
oxygen related signal differences as seen in BOLD-MRI [65]. It
has preclinically been confirmed that this novel technique is able
to monitor changes in tumor oxygenation (r = 0.51, p = 0.022)
and changes in lipid relaxation rates show moderate correlation
with absolute pO2 values (r = 0.37, p = 0.027) [66]. Another promis-
ing novel MR-technique is oxygen-enhanced (OE-)MRI, where
tumor oxygenation is detected as oxygen-induced increase in MR
signal that is generally larger than signal changes detected using
BOLD-MRI or MOBILE. By letting subjects breath 100% oxygen,
O2-saturation in arterial blood plasma (Hb-bound and dissolved)
will increase, resulting in an increase in tumor pO2 and tissue oxy-
genation [67]. In a preliminary study, 10 patients with advanced
abdominal/pelvic cancer underwent serial measurement of tumor
relaxation rate while breathing medical air (21% oxygen) followed
by 100% oxygen (OE-MRI). The resulting difference in MR signal
was significant (P < 0.005), proving the ability of OE-MRI to indi-
rectly detect changes in tumor oxygen levels [67,68]. When com-
bining multiple MRI-techniques with simultaneous PET-based
imaging (i.e., PET/MRI), complementary information in tumor per-
fusion, tissue oxygenation, metabolic activity, and oxygen con-
sumption could be acquired. Similar to PET/CT, this
multiparametric method could be used to validate novelhypoxia-associated biomarkers and may help elucidate the com-
plex nature of chronic hypoxia [69]. Moreover, PET/MRI relies on
highly sensitive PET-probes and highly specific anatomical and/or
functional MR information. However, protocol standardization
(i.e., execution and analyses) is needed to allow for reproducible
results and validation method of hypoxia-detection in multiple
clinics and tumor types.
Non-invasive imaging could be useful to monitor hypoxic status
and estimate early clinical response during (chemo)radiation treat-
ment. In non-responsive patients, treatment strategies could
adapted to more hypoxia-guided therapies [70]. In radiotherapy,
PET-based dose painting has been proposed to specifically deliver
an escalated radiation dose or boost to hypoxic sub-volumes
[71]. Such hypoxia-targeted radiotherapy could deliver an optimal
dose distribution to radio-resistant regions. Currently, the survival
probability of EC patients remains disappointing. Potentially, treat-
ment outcome and patient survival could be improved by targeting
hypoxia (i.e., increasing oxygen delivery, normalize tumor
vasculature, or reduce oxygen consumption) or by implicating
hypoxia-specific treatment strategies. However, pretreatment
hypoxic status must first be assessed since large patient- and
tumor-variability in oxygenation can exist. By selecting hypoxic
patients before the start of treatment, a window-of-opportunity
arises wherein attempts to reduce tumor hypoxia could be made.
By first applying hypoxia-specific treatment strategies to overcome
tumor hypoxia or eradicate hypoxic cells, conventional (chemo-)
radiotherapy may become more effective and better treatment
outcome can be achieved [47,70]. For example, preselected
patients with hypoxic laryngeal cancer (i.e., high CA IX-fraction)
had better LC and DFS when treated with accelerated radiotherapy
with carbogen breathing and nicotinamide (ARCON) compared to
accelerated radiotherapy (LC 97% vs. 71%, p < 0.01 and DFS 92%
vs. 69%, p = 0.06) [72]. In contrast, a reversed scheme of radiation
dose-painting has recently been proposed [73]. Here, hypoxic
tumor regions were preclinically assessed using 18F-HX4-PET/CT
imaging and used for radiation treatment dose planning. Non-
hypoxic regions (i.e., low 18F-HX-4 uptake) received an escalated
radiation dose, while hypoxic regions were targeted with
hypoxia-activated prodrugs (HAP). Interestingly, this strategy
was as effective as conventional radiotherapy plans but was able
to reduce the mean overall tumor dose and hereby lowering nor-
mal tissue toxicity. Radiation dose was therefore used more
efficiently.
It seems that hypoxia represents a ‘Janus face’ in tumor biology.
On the one hand, it is associated with restrained proliferation and
oxygen-deprived cell death, but on the other hand, it promotes
adaptive processes leading to tumor aggressiveness, progression,
and acquired resistance to treatment [74]. The high treatment fail-
ure rate seen in EC might therefore be due to a hypoxic
microenvironment.
Molecular imaging could help individualizing hypoxia-specific
treatment strategies in EC. Several approaches are available that
focus on targeting HIF-1a and VEGF. YC-1 (3-(50-hydroxymethyl-
20-furyl)-1-benzylindazole) suppresses esophageal tumor cell
growth and inhibit cellular migration activities [75]. Similarly,
radiosensitivity could be enhanced by downregulating VEGF and
HIF-1a protein levels. Drugs such as Ginsenoside Rg3, Fenofibrate,
and Berberine have been associated with anti-tumor and anti-
angiogenesis activities by promoting radiosensitivity of human
hypoxic EC cell lines [76–78]. By targeting CA IX expression, ther-
apeutic benefit could be improved when combining conventional
treatment with cytotoxic agents such as CA IX-directed ligands
or antibodies [79].
Another hypoxia-specific treatment strategy is the use of
hypoxia-activated prodrugs (HAP) that become activated by enzy-
matic reduction under hypoxic conditions to release cytotoxic
J. Peerlings et al. /Methods 130 (2017) 51–62 59effectors (‘‘warheads”). For example, evofosfamide (TH-302) is a
HAP that upon activation in severely hypoxic regions induces
DNA damage but also diffuses to the surrounding, better oxy-
genated, cells and creating cytotoxic bystander effects. TH-302
has demonstrated enhanced anti-tumor effects in combination
with (chemo)radiotherapy, although levels of toxicity were also
elevated [47,80]. In addition, significant clinical benefit has yet to
be reported for treatment strategies involving currently-available
HAP (i.e., monotherapy or combined with chemoradiotherapy)
[81]. We acknowledge the potential therapeutic effect of additional
anti-hypoxia treatment, but also the importance to limit unneces-
sary toxicity by selecting patients who will benefit from these
modifications. Extensive clinical testing of TH-302 in combination
with CCRT is therefore advised in pre-selected hypoxic patients
using for example HX4-PET imaging [70,80].
Although this systematic review adheres to the PRISMA
statement, it holds a few limitations [8]. Several clinicopathological
factors such as age, clinical stage, lymph node invasion, and
location (i.e., proximal or distal EC) were not investigated, but
could explain the different expression rate of hypoxia-associated
biomarkers in esophageal cancer. Furthermore, interactions
between these factors and treatment differences (e.g., radiation
dose, fractions, and chemo regimens) were not described. Beside
hypoxia, reactive oxygen species, genetic alterations and
inflammation may also be involved in the stimulation of
hypoxia-associated molecular responses. Finally, we did not assess
the effect of methodological differences across included studies
(e.g., IHC staining procedures, antibody supplier, slice thickness,
and threshold for hypoxic status). We assumed that reliable,
standardized protocols were applied correctly for optimal detec-
tion of hypoxia-associated markers. Although presumed to be
inconsequential, the possibility of impure comparison emphasizes
the need for protocol standardization.
5. Conclusion
Evaluation of tumor micro-environmental conditions, such
as intratumoral hypoxia, is important to predict treatment
outcome and efficacy. Until now, the predictive value of hypoxia-
associated biomarkers in esophageal cancer is controversially
discussed. Although there is increasing clinical evidence that
hypoxia-associated responses can be detected, the perfect
biomarker for tumor hypoxia in EC has not yet been established.
However, PET-based hypoxia imaging shows great potential in
evaluating hypoxic tumor status non-invasively. Knowledge of
the presence and dynamics of hypoxia in different esophageal can-
cer patients (ESCC vs. AC) is important to exploit and validate novel
therapeutic strategies directed against tumor hypoxia. The
window-of-opportunity trial concept paves the way for optimal
hypoxia diagnosis and individualized hypoxia-guided treatment
to improve radiotherapy response in EC patients. For personalized
cancer medicine, simple, safe, and efficient methods are needed to
determine tumor oxygenation in EC and help select patients
with hypoxic tumors. Presumably, the combination of multiple,
minimally invasive molecular markers is needed to fully evaluate
the hypoxic status in cancer patients.
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A1. Systematic search protocol
Research question
How does hypoxia affect treatment efficacy and outcome in
patients with esophageal cancer?
Search strategy
Web of Science: 182 hits. TOPIC: (hypoxia) OR TOPIC: (hypox⁄) AND
TOPIC: TS = (cancer) OR TS = (tumor) OR TS = (tumor) OR TS = (car-
cinoma) OR TS = (neoplasm) OR TS = (oncology) OR TS = (lymph
node) AND TOPIC: (esophag⁄) OR (oesophag⁄) OR (esophageal can-
cer) OR (oesophageal cancer) OR (esophageal carcinoma) OR (oeso-
phageal carcinoma) OR (esophageal tumor) OR (oesophageal
tumor) AND TOPIC: TS = (radioresistance) OR TS = (prognosis) OR
TS = (treatment outcome) OR TS = (tumor aggressiveness) OR
TS = (tumor spread) OR TS = (malignant progression) OR TS =
(metastasis) OR TS = (clinical outcome) OR TS = (response predic-
tion) OR TS = (pathological free survival) OR TS = (non-
responders) OR TS = (pathological response) OR TS = (treatment
resistance) OR TS = (therapy resistance) OR TS = (treatment
efficacy).
MEDLINE (MeSH): 22 hits. Search (((((((hypoxia[MeSH Terms])
AND ((((cancer[MeSH Terms]) OR oncology[MeSH Terms]) OR
tumor[MeSH Terms]) OR tumor[MeSH Terms])) AND ((((((radia-
tion therapy[MeSH Terms]) OR treatment outcome[MeSH Terms])
OR prognosis[MeSH Terms]) OR adjuvant chemotherapy[MeSH
Terms]) OR immunotherapy[MeSH Terms]) OR treatment resis-
tant[MeSH Terms])) AND (((((esophageal cancer[MeSH Terms])
OR oesophag⁄[MeSH Terms]) OR esophag⁄[MeSH Terms]) OR
lymph node[MeSH Terms]) or mediastin⁄ [MeSH Terms])))).
PubMed (Free text): 215 hits. ((((((((hypoxia) OR hypox⁄) OR
hypoxia-induced factor)) AND (((((((((((esophageal cancer) OR
esophag⁄) OR oesophageal cancer) OR mediastinum) OR lym-
phadenopathy) OR oesophageal carcinoma) OR esophageal tumor)
OR oesophageal tumor) OR esophageal carcinoma) OR lymph node)
AND (((((((((((((((radioresistance) OR prognosis) OR treatment out-
come) OR tumor aggressiveness) OR tumor spread) OR malignant
progression) OR metastasis) OR clinical outcome) OR response pre-
diction) OR pathological free survival) OR non-responders) OR
pathological response) OR treatment resistance) OR therapy resis-
tance) OR treatment efficacy)).
Inclusion criteria
P = PARTICIPANTS OR PATIENTS Species: human.
Age: adults (minimal age >18 yr.).
Sex: no restriction.
Condition: esophageal cancer.
Specimen: patients or biopsy-acquired tissue samples or surgi-
cal tissue samples.
Tumor type: Squamous cell carcinoma (SCC) and adenocarci-
noma (AC).
Stage: no restriction.
I = INDEX TEST. All clinical tests able to measure hypoxia-related
markers.
C = COMPARATIVE TEST. not relevant.
O = OUTCOME. Overall survival (OS), Disease-free survival (DSF).
S = STUDY DESIGN. Study design: original diagnostic experiments.
60 J. Peerlings et al. /Methods 130 (2017) 51–62Study type: full-text content available, no studies aiming to elu-
cidate molecular mechanisms of hypoxia.
Language: English.
Publication year: no restriction.
Exclusion criteria
Based on title & abstract.
Based on full text.
1. Irrelevant study, not meeting PICOS-characteristics.
2. preclinical studies using animal-based tumor models or eso-
phageal cell lines.
3. Reviews, letters to the editor, comments, supplements, confer-
ence abstracts, reports, essays, symposiums, guidelines.
4. Overlapping data-sets.
5. Survival analyses were not presented in publication.
6. Presented survival analyses did not allow correlation between
expression rate of hypoxia-associated markers and treatment
outcome analyses.
Data extraction
Elements that were extracted comprised of:
Patient characteristics: number of subjects included in the
study, country of origin, mean age of the patient population,
tumor cell type, specimen type.
Index test characteristics: method of quantifying hypoxia,
marker type, definition of hypoxia, percentage of hypoxic ele-
ments, selected treatment strategy.
Outcome parameters: statistical analysis (uni- or multivari-
ate), overall survival, disease free survival, complete response,
local control, p-values indicating statistical difference in treat-
ment outcome between high and low percentages of hypoxia-
associated markers.
Study characteristics: First author, publication year.
Finally, each article was given a unique identification number.
References
[1] M.R. Horsman, L.S. Mortensen, J.B. Petersen, M. Busk, J. Overgaard, Imaging
hypoxia to improve radiotherapy outcome, Nat. Rev. Clin. Oncol. 9 (2012) 674–
687.
[2] J. Overgaard, Hypoxic modification of radiotherapy in squamous cell
carcinoma of the head and neck–a systematic review and meta-analysis,
Radiother. Oncol. 100 (2011) 22–32.
[3] W. Ping, W. Sun, Y. Zu, W. Chen, X. Fu, Clinicopathological and prognostic
significance of hypoxia-inducible factor-1alpha in esophageal squamous cell
carcinoma: a meta-analysis, Tumour Biol. 35 (2014) 4401–4409.
[4] P. van Hagen, M. Hulshof, J. van Lanschot, E.W. Steyerberg, M.I.V. Henegouwen,
B.P.L. Wijnhoven, D.J. Richel, G.A.P. Nieuwenhuijzen, C. Group, Preoperative
chemoradiotherapy for esophageal or junctional cancer, N. Engl. J. Med. 366
(2012) 2074–2084.
[5] R.L. Siegel, K.D. Miller, A. Jemal, Cancer statistics, CA Cancer J. Clin. 66 (2016)
7–30.
[6] I. Brink, P. Baier, E. Juttner, T. Paulus, M. Narayanan, U. Podbielski, W. Weber,
M. Hentschel, Assessment of hypoxia in esophageal carcinomas using 18F-
MISO PET, Journal of nuclear medicine: official publication, Soci. Nucl. Med. 49
(2008).
[7] L.H. Gray, A.D. Conger, M. Ebert, S. Hornsey, O.C. Scott, The concentration of
oxygen dissolved in tissues at the time of irradiation as a factor in
radiotherapy, Br. J. Radiol. 26 (1953) 638–648.
[8] D. Moher, A. Liberati, J. Tetzlaff, D.G. Altman, Preferred reporting items for
systematic reviews and meta-analyses: the PRISMA statement, J. Clin.
Epidemiol. 62 (2009) 1006–1012.
[9] P. Birner, B. Jesch, J. Friedrich, M. Riegler, J. Zacherl, M. Hejna, F. Wrba, A.
Schultheis, S.F. Schoppmann, Carbonic anhydrase IX overexpression is
associated with diminished prognosis in esophageal cancer and correlates
with her-2 expression, Ann. Surg. Oncol. 18 (2011) 3330–3337.
[10] Y.S. Chen, Y. Lu, C.L. Lu, L. Zhang, Beclin-1 expression is a predictor of clinical
outcome in patients with esophageal squamous cell carcinoma and correlated
to hypoxia-inducible factor (HIF)-1 alpha expression, Pathol. Oncol. Res. 15
(2009) 487–493.
[11] I. Chiba, K. Ogawa, T. Morioka, H. Shimoji, N. Sunagawa, S. Iraha, T. Nishimaki,
N. Yoshimi, S. Murayama, Clinical significance of GLUT-1 expression inpatients with esophageal cancer treated with concurrent
chemoradiotherapy, Oncol. Lett. 2 (2011) 21–28.
[12] A. Driessen, W. Landuyt, S. Pastorekova, J. Moons, L. Goethals, K. Haustermans,
P. Nafteux, F. Penninckx, K. Geboes, T. Lerut, N. Ectors, Expression of carbonic
anhydrase IX (CA IX), a hypoxia-related protein, rather than vascular-
endothelial growth factor (VEGF), a pro-angiogenic factor, correlates with an
extremely poor prognosis in esophageal and gastric adenocarcinomas, Ann.
Surg. 243 (2006) 334–340.
[13] G. Jomrich, B. Jesch, P. Birner, K. Schwameis, M. Paireder, R. Asari, S.F.
Schoppmann, Stromal expression of carbonic anhydrase IX in esophageal
cancer, Clin. Transl. Oncol. 16 (2014) 966–972.
[14] M. Katsuta, M. Miyashita, H. Makino, T. Nomura, S. Shinji, K. Yamashita, T.
Tajiri, M. Kudo, T. Ishiwata, Z. Naito, Correlation of hypoxia inducible factor-1
alpha with lymphatic metastasis via vascular endothelial growth factor-C in
human esophageal cancer, Exp. Mol. Pathol. 78 (2005) 123–130.
[15] S. Kimura, Y. Kitadai, S. Tanaka, T. Kuwai, J. Hihara, K. Yoshida, T. Toge, K.
Chayama, Expression of hypoxia-inducible factor (HIF)-1 alpha is associated
with vascular endothelial growth factor expression and tumour anglogenesis
in human oesophageal squamous cell carcinoma, Eur. J. Cancer 40 (2004)
1904–1912.
[16] M.I. Koukourakis, A. Giatromanolaki, J. Skarlatos, L. Corti, S. Blandamura, M.
Piazza, K.C. Gatter, A.L. Harris, Hypoxia inducible factor (HIF-1a and HIF-2a)
expression in early esophageal cancer and response to photodynamic therapy
and radiotherapy, Cancer Res. 61 (2001) 1830–1832.
[17] T. Kurokawa, M. Miyamoto, K. Kato, Y. Cho, Y. Kawarada, Y. Hida, T. Shinohara,
T. Itoh, S. Okushiba, S. Kondo, H. Katoh, Overexpression of hypoxia-inducible-
factor 1 alpha(HIF-1 alpha) in oesophageal squamous cell carcinoma correlates
with lymph node metastasis and pathologic stage, Br. J. Cancer 89 (2003)
1042–1047.
[18] F.C. Ling, N. Leimbach, S.E. Baldus, S. Buechel, S. Neiss, J. Brabender, U. Drebber,
H.P. Dienes, R.P. Mueller, A.H. Hoelscher, P.M. Schneider, HIF-1alpha mRNA is
not associated with histopathological regression following neoadjuvant
chemoradiation in esophageal cancer, Anticancer Res. 26 (2006) 4505–4509.
[19] T. Matsuyama, K. Nakanishi, T. Hayashi, Y. Yoshizumi, S. Aiko, Y. Sugiura, T.
Tanimoto, M. Uenoyama, Y. Ozeki, T. Maehara, Expression of hypoxia-
inducible factor-1 alpha in esophageal squamous cell carcinoma, Cancer Sci.
96 (2005) 176–182.
[20] P.C. Munipalle, Y.K.S. Viswanath, P.A. Davis, D. Scoones, Prognostic value of
hypoxia inducible factor 1 alpha in esophageal squamous cell carcinoma, Dis.
Esophagus 24 (2011) 177–181.
[21] N. Ogane, M. Yasuda, M. Shimizu, M. Miyazawa, S. Kamoshida, A. Ueda, K.
Takata, Y. Sakuma, Y. Miyagi, Y. Kameda, Clinicopathological implications of
expressions of hypoxia-related molecules in esophageal superficial squamous
cell carcinoma, Ann. Diagn. Pathol. 14 (2010) 23–29.
[22] K. Ogawa, I. Chiba, T. Morioka, H. Shimoji, W. Tamaki, R. Takamatsu, T.
Nishimaki, N. Yoshimi, S. Murayama, Clinical significance of HIF-l alpha
expression in patients with esophageal cancer treated with concurrent
chemoradiotherapy, Anticancer Res. 31 (2011) 2351–2359.
[23] L.M.A. Schreurs, J.K. Smit, K. Pavlov, B.B. Pultrum, J. Pruim, H. Groen, H.
Hollema, J.T.M. Plukker, Prognostic impact of clinicopathological features and
expression of biomarkers related to F-18-FDG uptake in esophageal cancer,
Ann. Surg. Oncol. 21 (2014) 3751–3757.
[24] M. Sohda, H. Ishikawa, N. Masuda, H. Kato, T. Miyazaki, M. Nakajima, M.
Fukuchi, R. Manda, Y. Fukai, H. Sakurai, H. Kuwano, Pretreatment evaluation of
combined HIF-1alpha, p53 and p21 expression is a useful and sensitive
indicator of response to radiation and chemotherapy in esophageal cancer, Int.
J. Cancer 110 (2004) 838–844.
[25] H. Takala, J. Saarnio, H. Wiik, P. Ohtonen, Y. Soini, HIF-1 alpha and VEGF are
associated with disease progression in esophageal carcinoma, J. Surg. Res. 167
(2011) 41–48.
[26] N. Tanaka, H. Kato, T. Inose, H. Kimura, A. Faried, M. Sohda, M. Nakajima, Y.
Fukai, T. Miyazaki, N. Masuda, M. Fukuchi, H. Kuwano, Expression of carbonic
anhydrase 9, a potential intrinsic marker of hypoxia, is associated with poor
prognosis in oesophageal squamous cell carcinoma, Br. J. Cancer 99 (2008)
1468–1475.
[27] C. Tzao, S.C. Lee, H.J. Tung, H.S. Hsu, W.H. Hsu, G.H. Sun, C.P. Yu, J.S. Jin,
Y.L. Cheng, Expression of hypoxia-inducible factor (HIF)-1 alpha and
vascular endothelial growth factor (VEGF)-D as outcome predictors in
resected esophageal squamous cell carcinoma, Dis. Markers 25 (2008)
141–148.
[28] M. Winther, J. Alsner, T. Tramm, M. Nordsmark, Hypoxia-regulated gene
expression and prognosis in loco-regional gastroesophageal cancer, Acta
Oncol. (Stockholm, Sweden) 52 (2013) 1327–1335.
[29] J. Yue, Y. Yang, A.R. Cabrera, X. Sun, S. Zhao, P. Xie, J. Zheng, L. Ma, Z. Fu, J. Yu,
Measuring tumor hypoxia with (1)(8)F-FETNIM PET in esophageal squamous
cell carcinoma: a pilot clinical study, Dis. Esophagus 25 (2012) 54–61.
[30] L. Zhang, S.B. Ye, Z.L. Li, G. Ma, S.P. Chen, J. He, W.L. Liu, D. Xie, Y.X. Zeng, J. Li,
Increased HIF-1alpha expression in tumor cells and lymphocytes of tumor
microenvironments predicts unfavorable survival in esophageal squamous cell
carcinoma patients, Int. J. Clin. Exp. Pathol. 7 (2014) 3887–3897.
[31] G.L. Semenza, HIF-1 and tumor progression: pathophysiology and
therapeutics, Trends Mol. Med. 8 (2002) S62–S67.
[32] B. Krishnamachary, M.F. Penet, S. Nimmagadda, Y. Mironchik, V. Raman, M.
Solaiyappan, G.L. Semenza, M.G. Pomper, Z.M. Bhujwalla, Hypoxia regulates
CD44 and its variant isoforms through HIF-1alpha in triple negative breast
cancer, PLoS One 7 (2012) e44078.
J. Peerlings et al. /Methods 130 (2017) 51–62 61[33] S.J. van Kuijk, A. Yaromina, R. Houben, R. Niemans, P. Lambin, L.J. Dubois,
Prognostic significance of carbonic anhydrase IX expression in cancer patients:
a meta-analysis, Front. Oncol. 6 (2016) 69.
[34] U.R. Jewell, I. Kvietikova, A. Scheid, C. Bauer, R.H. Wenger, M. Gassmann,
Induction of HIF-1alpha in response to hypoxia is instantaneous, FASEB J. 15
(2001) 1312–1314.
[35] S.G. Peeters, C.M. Zegers, A. Yaromina, W. Van Elmpt, L. Dubois, P. Lambin,
Current preclinical and clinical applications of hypoxia PET imaging using 2-
nitroimidazoles, Q. J. Nucl. Med. Mol. Imaging 59 (2015) 39–57.
[36] S.G. Peeters, C.M. Zegers, N.G. Lieuwes, W. van Elmpt, J. Eriksson, G.A. van
Dongen, L. Dubois, P. Lambin, A comparative study of the hypoxia PET tracers
[(1)(8)F]HX4, [(1)(8)F]FAZA, and [(1)(8)F]FMISO in a preclinical tumor model,
Int. J. Radiat. Oncol. Biol. Phys. 91 (2015) 351–359.
[37] C.M. Zegers, F.J. Hoebers, W. van Elmpt, J.A. Bons, M.C. Ollers, E.G. Troost, D.
Eekers, L. Balmaekers, M. Arts-Pechtold, F.M. Mottaghy, P. Lambin, Evaluation
of tumour hypoxia during radiotherapy using [18F]HX4 PET imaging and
blood biomarkers in patients with head and neck cancer, Eur. J. Nucl. Med.
Mol. Imaging 43 (2016) 2139–2146.
[38] C.M. Zegers, W. van Elmpt, F.J. Hoebers, E.G. Troost, M.C. Ollers, F.M. Mottaghy,
P. Lambin, Imaging of tumour hypoxia and metabolism in patients with head
and neck squamous cell carcinoma, Acta Oncol. (Stockholm, Sweden) 54
(2015) 1378–1384.
[39] C.M. Zegers, W. van Elmpt, B. Reymen, A.J. Even, E.G. Troost, M.C. Ollers, F.J.
Hoebers, R.M. Houben, J. Eriksson, A.D. Windhorst, F.M. Mottaghy, D. De
Ruysscher, P. Lambin, In vivo quantification of hypoxic and metabolic status of
NSCLC tumors using [18F]HX4 and [18F]FDG-PET/CT imaging, Clin. Cancer Res.
20 (2014) 6389–6397.
[40] C.M. Zegers, W. van Elmpt, K. Szardenings, H. Kolb, A. Waxman, R.M.
Subramaniam, D.H. Moon, J.C. Brunetti, S.M. Srinivas, P. Lambin, D. Chien,
Repeatability of hypoxia PET imaging using [(1)(8)F]HX4 in lung and head and
neck cancer patients: a prospective multicenter trial, Eur. J. Nucl. Med. Mol.
Imaging 42 (2015) 1840–1849.
[41] C.M. Zegers, W. van Elmpt, R. Wierts, B. Reymen, H. Sharifi, M.C. Ollers, F.
Hoebers, E.G. Troost, R. Wanders, A. van Baardwijk, B. Brans, J. Eriksson, B.
Windhorst, F.M. Mottaghy, D. De Ruysscher, P. Lambin, Hypoxia imaging with
[(1)(8)F]HX4 PET in NSCLC patients: defining optimal imaging parameters,
Radiother. Oncol. 109 (2013) 58–64.
[42] I.N. Fleming, R. Manavaki, P.J. Blower, C. West, K.J. Williams, A.L. Harris, J.
Domarkas, S. Lord, C. Baldry, F.J. Gilbert, Imaging tumour hypoxia with
positron emission tomography, Br. J. Cancer 112 (2015) 238–250.
[43] E.M. Hammond, M.C. Asselin, D. Forster, J.P. O’Connor, J.M. Senra, K.J. Williams,
The meaning, measurement and modification of hypoxia in the laboratory and
the clinic, Clin. Oncol. (Royal College of Radiologists (Great Britain)) 26 (2014)
277–288.
[44] R. Klaassen, R.J. Bennink, G. van Tienhoven, M.F. Bijlsma, M.G.H. Besselink, M.I.
V. Henegouwen, J.W. Wilmink, A.J. Nederveen, A.D. Windhorst, M. Hulshof, H.
W.M. van Laarhoven, Feasibility and repeatability of PET with the hypoxia
tracer F-18 HX4 in oesophageal and pancreatic cancer, Radiother. Oncol. 116
(2015) 94–99.
[45] E.E. Verwer, F.H. van Velden, I. Bahce, M. Yaqub, R.C. Schuit, A.D. Windhorst, P.
Raijmakers, A.A. Lammertsma, E.F. Smit, R. Boellaard, Pharmacokinetic
analysis of [18F]FAZA in non-small cell lung cancer patients, Eur. J. Nucl.
Med. Mol. Imaging 40 (2013) 1523–1531.
[46] E.E. Verwer, C.M. Zegers, W. van Elmpt, R. Wierts, A.D. Windhorst, F.M.
Mottaghy, P. Lambin, R. Boellaard, Pharmacokinetic modeling of a novel
hypoxia PET tracer [18F]HX4 in patients with non-small cell lung cancer,
EJNMMI Phys. 3 (2016) 30.
[47] R. Larue, L. Van de Voorde, M. Berbee, W.J.C. van Elmpt, L.J. Dubois, K.M. Panth,
S. Peeters, A. Claessens, W.M.J. Schreurs, M. Nap, F. Warmerdam, F.L.G.
Erdkamp, M.N. Sosef, P. Lambin, A phase 1 ’window-of-opportunity’ trial
testing evofosfamide (TH-302), a tumour-selective hypoxia-activated
cytotoxic prodrug, with preoperative chemoradiotherapy in oesophageal
adenocarcinoma patients, BMC Cancer 16 (2016) 8.
[48] L.J. Dubois, N.G. Lieuwes, M.H. Janssen, W.J. Peeters, A.D. Windhorst, J.C. Walsh,
H.C. Kolb, M.C. Ollers, J. Bussink, G.A. van Dongen, A. van der Kogel, P. Lambin,
Preclinical evaluation and validation of [18F]HX4, a promising hypoxia marker
for PET imaging, Proc. Natl. Acad. Sci. U.S.A. 108 (2011) 14620–14625.
[49] J. van Loon, M.H. Janssen, M. Ollers, H.J. Aerts, L. Dubois, M. Hochstenbag, A.M.
Dingemans, R. Lalisang, B. Brans, B. Windhorst, G.A. van Dongen, H. Kolb, J.
Zhang, D. De Ruysscher, P. Lambin, PET imaging of hypoxia using [18F]HX4: a
phase I trial, Eur. J. Nucl. Med. Mol. Imaging 37 (2010) 1663–1668.
[50] E.E. Graves, R.J. Hicks, D. Binns, M. Bressel, Q.T. Le, L. Peters, R.J. Young, D.
Rischin, Quantitative and qualitative analysis of [(18)F]FDG and [(18)F]FAZA
positron emission tomography of head and neck cancers and associations with
HPV status and treatment outcome, Eur. J. Nucl. Med. Mol. Imaging 43 (2016)
617–625.
[51] H. Yuan, T. Schroeder, J.E. Bowsher, L.W. Hedlund, T. Wong, M.W. Dewhirst,
Intertumoral differences in hypoxia selectivity of the PET imaging agent 64Cu
(II)-diacetyl-bis(N4-methylthiosemicarbazone), J. Nucl. Med. 47 (2006) 989–
998.
[52] K.S. Chao, W.R. Bosch, S. Mutic, J.S. Lewis, F. Dehdashti, M.A. Mintun, J.F.
Dempsey, C.A. Perez, J.A. Purdy, M.J. Welch, A novel approach to overcome
hypoxic tumor resistance: Cu-ATSM-guided intensity-modulated radiation
therapy, Int. J. Radiat. Oncol. Biol. Phys. 49 (2001) 1171–1182.
[53] B.A. Hoeben, J.H. Kaanders, G.M. Franssen, E.G. Troost, P.F. Rijken, E.
Oosterwijk, G.A. van Dongen, W.J. Oyen, O.C. Boerman, J. Bussink, PET ofhypoxia with 89Zr-labeled cG250-F(ab’)2 in head and neck tumors, J. Nucl.
Med. 51 (2010) 1076–1083.
[54] V. Akurathi, L. Dubois, S. Celen, N.G. Lieuwes, S.K. Chitneni, B.J. Cleynhens, A.
Innocenti, C.T. Supuran, A.M. Verbruggen, P. Lambin, G.M. Bormans,
Development and biological evaluation of (9)(9)mTc-sulfonamide derivatives
for in vivo visualization of CA IX as surrogate tumor hypoxia markers, Eur. J.
Med. Chem. 71 (2014) 374–384.
[55] L. Dubois, N.G. Lieuwes, A. Maresca, A. Thiry, C.T. Supuran, A. Scozzafava, B.G.
Wouters, P. Lambin, Imaging of CA IX with fluorescent labelled sulfonamides
distinguishes hypoxic and (re)-oxygenated cells in a xenograft tumour model,
Radiother. Oncol. 92 (2009) 423–428.
[56] D. Sneddon, R. Niemans, M. Bauwens, A. Yaromina, S.J. van Kuijk, N.G. Lieuwes,
R. Biemans, I. Pooters, P.A. Pellegrini, N.A. Lengkeek, I. Greguric, K.F. Tonissen,
C.T. Supuran, P. Lambin, L. Dubois, S.A. Poulsen, Synthesis and in vivo
biological evaluation of (68)Ga-labeled carbonic anhydrase IX targeting
small molecules for positron emission tomography, J. Med. Chem. 59 (2016)
6431–6443.
[57] M. Matsuo, S. Matsumoto, J.B. Mitchell, M.C. Krishna, K. Camphausen,
Magnetic resonance imaging of the tumor microenvironment in
radiotherapy: perfusion, hypoxia, and metabolism, Semin. Radiat. Oncol. 24
(2014) 210–217.
[58] C. Halle, E. Andersen, M. Lando, E.K. Aarnes, G. Hasvold, M. Holden, R.G.
Syljuasen, K. Sundfor, G.B. Kristensen, R. Holm, E. Malinen, H. Lyng, Hypoxia-
induced gene expression in chemoradioresistant cervical cancer revealed by
dynamic contrast-enhanced MRI, Cancer Res. 72 (2012) 5285–5295.
[59] P.J. Hoskin, D.M. Carnell, N.J. Taylor, R.E. Smith, J.J. Stirling, F.M. Daley, M.I.
Saunders, S.M. Bentzen, D.J. Collins, J.A. d’Arcy, A.P. Padhani, Hypoxia in
prostate cancer: correlation of BOLD-MRI with pimonidazole
immunohistochemistry-initial observations, Int. J. Radiat. Oncol. Biol. Phys.
68 (2007) 1065–1071.
[60] Y. Wang, M. Liu, M.L. Jin, Blood oxygenation level-dependent magnetic
resonance imaging of breast cancer: correlation with carbonic anhydrase IX
and vascular endothelial growth factor, Chin. Med. J. (Engl) 130 (2017) 71–76.
[61] A.R. Padhani, K.A. Krohn, J.S. Lewis, M. Alber, Imaging oxygenation of human
tumours, Eur. Radiol. 17 (2007) 861–872.
[62] A. Yaromina, H. Thames, X. Zhou, S. Hering, W. Eicheler, A. Dorfler, T. Leichtner,
D. Zips, M. Baumann, Radiobiological hypoxia, histological parameters of
tumour microenvironment and local tumour control after fractionated
irradiation, Radiother. Oncol. 96 (2010) 116–122.
[63] D. Zips, S. Boke, T. Kroeber, A. Meinzer, K. Bruchner, H.D. Thames, M. Baumann,
A. Yaromina, Prognostic value of radiobiological hypoxia during fractionated
irradiation for local tumor control, Strahlenther. Onkol. 187 (2011) 306–310.
[64] U. Simoncic, S. Leibfarth, S. Welz, N. Schwenzer, H. Schmidt, G. Reischl, C.
Pfannenberg, C. Fougere, K. Nikolaou, D. Zips, D. Thorwarth, Comparison of
DCE-MRI kinetic parameters and FMISO-PET uptake parameters in head and
neck cancer patients, Med. Phys. (2017).
[65] B.F. Jordan, J. Magat, F. Colliez, E. Ozel, A.C. Fruytier, V. Marchand, L. Mignion, C.
Bouzin, P.D. Cani, C. Vandeputte, O. Feron, N. Delzenne, U. Himmelreich, V.
Denolin, T. Duprez, B. Gallez, Mapping of oxygen by imaging lipids relaxation
enhancement: a potential sensitive endogenous MRI contrast to map
variations in tissue oxygenation, Magn. Reson. Med. 70 (2013) 732–744.
[66] F. Colliez, M.A. Neveu, J. Magat, T.T. Cao Pham, B. Gallez, B.F. Jordan,
Qualification of a noninvasive magnetic resonance imaging biomarker to
assess tumor oxygenation, Clin. Cancer Res. 20 (2014) 5403–5411.
[67] J.P. O’Connor, J.H. Naish, G.J. Parker, J.C. Waterton, Y. Watson, G.C. Jayson, G.A.
Buonaccorsi, S. Cheung, D.L. Buckley, D.M. McGrath, C.M. West, S.E. Davidson,
C. Roberts, S.J. Mills, C.L. Mitchell, L. Hope, N.C. Ton, A. Jackson, Preliminary
study of oxygen-enhanced longitudinal relaxation in MRI: a potential novel
biomarker of oxygenation changes in solid tumors, Int. J. Radiat. Oncol. Biol.
Phys. 75 (2009) 1209–1215.
[68] J.P. O’Connor, J.K. Boult, Y. Jamin, M. Babur, K.G. Finegan, K.J. Williams, R.A.
Little, A. Jackson, G.J. Parker, A.R. Reynolds, J.C. Waterton, S.P. Robinson,
Oxygen-enhanced MRI accurately identifies, quantifies, and maps tumor
hypoxia in preclinical cancer models, Cancer Res. 76 (2016) 787–795.
[69] W. van Elmpt, C.M. Zegers, B. Reymen, A.J. Even, A.M. Dingemans, M. Oellers, J.
E. Wildberger, F.M. Mottaghy, M. Das, E.G. Troost, P. Lambin, Multiparametric
imaging of patient and tumour heterogeneity in non-small-cell lung cancer:
quantification of tumour hypoxia, metabolism and perfusion, Eur. J. Nucl. Med.
Mol. Imaging 43 (2016) 240–248.
[70] L.J. Dubois, R. Niemans, S.J. van Kuijk, K.M. Panth, N.K. Parvathaneni, S.G.
Peeters, C.M. Zegers, N.H. Rekers, M.W. van Gisbergen, R. Biemans, N.G.
Lieuwes, L. Spiegelberg, A. Yaromina, J.Y. Winum, M. Vooijs, P. Lambin, New
ways to image and target tumour hypoxia and its molecular responses,
Radiother. Oncol. 116 (2015) 352–357.
[71] A.J. Even, J. van der Stoep, C.M. Zegers, B. Reymen, E.G. Troost, P. Lambin, W.
van Elmpt, PET-based dose painting in non-small cell lung cancer: Comparing
uniform dose escalation with boosting hypoxic and metabolically active sub-
volumes, Radiother. Oncol. 116 (2015) 281–286.
[72] Saskia E. Rademakers, Ilse J. Hoogsteen, Paul F. Rijken, Egbert Oosterwijk, Chris
H. Terhaard, Patricia A. Doornaert, Johannes A. Langendijk, Piet van den Ende,
Robert Takes, Remco De Bree, Albert J. van der Kogel, Johan Bussink, J.H.
Kaanders, Pattern of CAIX expression is prognostic for outcome and predicts
response to ARCON in patients with laryngeal cancer treated in a phase III
randomized trial, Radiat. Oncol. J. 108 (2013) 517–522.
[73] A. Yaromina, M. Granzier, R. Biemans, N.G. Lieuwes, W. Van Elmpt, G. Shakirin,
L. Dubois, P. Lambin, A novel concept for tumour targeting with radiation:
62 J. Peerlings et al. /Methods 130 (2017) 51–62inverse dose-painting or targeting the ‘‘Low Drug Uptake Volume”, Radiother.
Oncol. (2017).
[74] J.L. Tatum, G.J. Kelloff, R.J. Gillies, J.M. Arbeit, J.M. Brown, K.S. Chao, J.D.
Chapman, W.C. Eckelman, A.W. Fyles, A.J. Giaccia, R.P. Hill, C.J. Koch, M.C.
Krishna, K.A. Krohn, J.S. Lewis, R.P. Mason, G. Melillo, A.R. Padhani, G. Powis, J.
G. Rajendran, R. Reba, S.P. Robinson, G.L. Semenza, H.M. Swartz, P. Vaupel, D.
Yang, B. Croft, J. Hoffman, G. Liu, H. Stone, D. Sullivan, Hypoxia: importance in
tumor biology, noninvasive measurement by imaging, and value of its
measurement in the management of cancer therapy, Int. J. Radiat. Biol. 82
(2006) 699–757.
[75] Y. Feng, H. Zhu, T. Ling, B. Hao, G. Zhang, R. Shi, Effects of YC-1 targeting
hypoxia-inducible factor 1 alpha in oesophageal squamous carcinoma cell line
Eca109 cells, Cell Biol. Int. 35 (2011) 491–497.
[76] X.L. Ge, F.X. Zhen, B.X. Yang, X. Yang, J. Cai, C. Zhang, S. Zhang, Y.D. Cao, J.X. Ma,
H.Y. Cheng, X.C. Sun, Ginsenoside Rg3 enhances radiosensitization of hypoxic
oesophageal cancer cell lines through vascular endothelial growth factor and
hypoxia inducible factor 1 alpha, J. Int. Med. Res. 42 (2014) 628–640.
[77] Y.Y. Ge, J. Liu, X. Yang, H.C. Zhu, B.X. Yang, K.L. Zhao, Z.J. Wu, G.J. Cheng, F.
Wang, F. Ni, Q. Ge, Y.G. Yang, G.M. Tai, X.C. Sun, J. Cai, Fenofibrate enhances
radiosensitivity of esophageal squamous cell carcinoma by suppressinghypoxia-inducible factor-1 alpha expression, Tumor Biol. 35 (2014) 10765–
10771.
[78] X. Yang, B.X. Yang, J. Cai, C. Zhang, Q. Zhang, L.P. Xu, Q. Qin, H.C. Zhu, J.X. Ma, G.
Z. Tao, H.Y. Cheng, X.C. Sun, Berberine enhances radiosensitivity of esophageal
squamous cancer by targeting HIF-1 alpha in vitro and in vivo, Cancer Biol.
Ther. 14 (2013) 1068–1073.
[79] P.C. McDonald, S. Dedhar, Carbonic anhydrase IX (CAIX) as a mediator of
hypoxia-induced stress response in cancer cells, Subcell. Biochem. 75 (2014)
255–269.
[80] S.G. Peeters, C.M. Zegers, R. Biemans, N.G. Lieuwes, R.G. van Stiphout, A.
Yaromina, J.D. Sun, C.P. Hart, A.D. Windhorst, W. van Elmpt, L.J. Dubois, P.
Lambin, TH-302 in combination with radiotherapy enhances the therapeutic
outcome and is associated with pretreatment [18F]HX4 hypoxia PET imaging,
Clin. Cancer Res. 21 (2015) 2984–2992.
[81] N. Baran, M. Konopleva, Molecular pathways: hypoxia-activated prodrugs in
cancer therapy, Clin. Cancer Res. (2017).
[82] D. Di Perri, J.A. Lee, A. Bol, F.X. Hanin, G. Janssens, D. Labar, A. Robert, E. Sterpin,
X. Geets, Evolution of [18F]fluorodeoxyglucose and [18F]fluoroazomycin
arabinoside PET uptake distributions in lung tumours during radiation
therapy, Acta Oncol. (Stockholm, Sweden) 56 (2017) 516–524.
